Search company, investor...
Stelis Biopharma company logo

Stelis Biopharma


Series C | Alive

Total Raised




Last Raised

$125M | 2 yrs ago

About Stelis Biopharma

Stelis Biopharma is a vertically integrated biopharmaceutical company with R&D, process scale-up and end-to-end manufacturing capabilities from drug substance to finished drug products in all injectable formats.

Headquarters Location

#293, Jigani Link Road, Bommasandra, Anekal Taluk

Bengaluru, 560 105,


+91 80 6784 0444

Missing: Stelis Biopharma's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Stelis Biopharma's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Stelis Biopharma

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Stelis Biopharma is included in 1 Expert Collection, including Biopharma Tech.


Biopharma Tech

5,241 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Stelis Biopharma Patents

Stelis Biopharma has filed 5 patents.

patents chart

Application Date

Grant Date


Related Topics




Diabetes, Peptide hormones, Proteins, Molecular biology, Insulin therapies


Application Date


Grant Date



Related Topics

Diabetes, Peptide hormones, Proteins, Molecular biology, Insulin therapies



Latest Stelis Biopharma News

Stelis Biopharma receives EIR from the US FDA for Drug-Device Combination Products

Jan 18, 2023

The US FDA’s EIR is received for the drug-device combination to be commercialised from the Stelis Pharma's flagship facility in Bengaluru, India January 18, 2023 / 11:20 AM IST The FDA had in September 2022 issued Stelis Pharma an EIR based on on-site Pre-Approval Inspection (PAI), and then in December 2022, the first product approval for one of its key customers (Image Source: Shutterstock) Trade × Stelis Biopharma has received an Establishment Inspection Report (EIR) from the United States Food and Drug Administration (US FDA), after the successful closure of its inspection specific to Drug-Device Combination Products to be commercialised at its flagship Bengaluru facility, it told the bourses on January 18. At the time of writing, Stelis Biopharma’s parent company, Strides Pharma Science was quoting at Rs 333.05, up Rs 0.15, or 0.05 percent. Founder Arun Kumar said they are “delighted” with the successful inspection, adding that they have “significant capacities established, and customers onboarded”. “Several of our customers' key fillings will now progress towards nearer-term approvals leading to an uptick in our CDMO revenues. We remain excited about the strategic progress that the company has made so far and are confident of delivering better business outcomes,” Kumar said. Stelis, which is a fully integrated biopharmaceutical contract development and manufacturing organisation (CDMO), had the US FDA conduct an Abbreviated Quality System Inspection Technique (QSIT) drug preapproval on-site inspection. Related stories

Stelis Biopharma Frequently Asked Questions (FAQ)

  • Where is Stelis Biopharma's headquarters?

    Stelis Biopharma's headquarters is located at #293, Jigani Link Road, Bommasandra, Anekal Taluk, Bengaluru.

  • What is Stelis Biopharma's latest funding round?

    Stelis Biopharma's latest funding round is Series C.

  • How much did Stelis Biopharma raise?

    Stelis Biopharma raised a total of $195M.

  • Who are the investors of Stelis Biopharma?

    Investors of Stelis Biopharma include Route One Ventures, Think Investments, Mankekar Family Office, TPG Growth, GMS Holdings and 3 more.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.